NYSE$GMED
Globus Medical Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Globus Medical reported strong revenue growth in Q4 2024, driven by the NuVasive acquisition and increased sales of spine products and enabling technology.
Globus Medical achieved Q4 2024 revenue of $657.3 million, reflecting a 6.6% increase year-over-year. GAAP net income reached $26.5 million, while non-GAAP net income stood at $117.4 million. Non-GAAP diluted EPS was $0.84, marking a 35.7% improvement from Q4 2023. The company's U.S. sales grew by 6.3%, while international sales increased by 7.7%.
- Q4 2024 revenue increased by 6.6% year-over-year to $657.3 million.
- GAAP net income surged 76.3% to $26.5 million.
- Non-GAAP diluted EPS rose 35.7% to $0.84.
- International revenue growth outpaced U.S. sales with an 8.9% increase on a constant currency basis.
Headline financials
Revenue & EPS history
Globus Medical · Revenue · Quarterly
$657M
Revenue by segment
Globus Medical · $375M total across 2 segments · Q3 2023
- Musculoskeletal Solutions$347M+51.0%92.6%
- Enabling Technologies$27.7M+14.8%7.4%
Forward guidance
Globus Medical reaffirms its 2025 revenue guidance of $2.66B to $2.69B, with expected non-GAAP EPS between $3.40 and $3.50. Following the anticipated Nevro acquisition, full-year revenue is projected to reach $2.80B to $2.90B, with non-GAAP EPS of $3.10 to $3.40.
Tailwinds
- Expected revenue growth to $2.66B-$2.69B in 2025.
- Non-GAAP EPS guidance set between $3.40-$3.50.
- Further revenue increase expected post-Nevro acquisition.
- Continued operational efficiencies and cost management focus.
- Ongoing investment in innovation and spine technology solutions.
Headwinds
- Potential integration challenges with Nevro acquisition.
- Foreign currency fluctuations may impact financial results.
- Increased competition in the musculoskeletal technology market.
- Macroeconomic uncertainties could affect demand.
- Regulatory risks associated with product approvals and compliance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+0.8%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.9%
Avg return
30 days after
57%
34 / 60 earnings
Positive
+36.0%
Q3 2025
Best reaction
-23.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -14.6% | -10.4% | |
| Q4 2025 | +4.6% | +2.1% | -8.8% | |
| Q3 2025 | +36.0% | +37.3% | +47.6% | |
| Q1 2025 | -23.0% | -19.7% | -17.3% | |
| Q4 2024 | -4.6% | -4.9% | -12.5% | |
| Q3 2024 | +10.7% | +8.2% | +11.2% | |
| Q2 2024 | +4.0% | +8.0% | +4.4% | |
| Q1 2024 | +22.8% | +28.7% | +31.6% | |
| Q4 2023 | +2.2% | +4.6% | -3.1% | |
| Q3 2023 | -1.4% | -5.1% | -2.5% | |
| Q2 2023 | -5.0% | -4.8% | -9.1% | |
| Q1 2023 | +2.9% | -0.3% | -1.8% | |
| Q4 2022 | -1.2% | -21.9% | -29.2% | |
| Q3 2022 | -4.2% | +9.4% | +11.5% | |
| Q2 2022 | +5.4% | +6.9% | -2.4% | |
| Q1 2022 | +0.1% | +5.2% | +0.1% | |
| Q4 2021 | -3.1% | -3.7% | +1.3% | |
| Q3 2021 | +0.2% | -4.3% | -19.4% | |
| Q2 2021 | -3.3% | -3.0% | +1.3% | |
| Q1 2021 | +3.1% | +3.0% | -0.9% | |
| Q4 2020 | -5.7% | -5.2% | -10.2% | |
| Q3 2020 | +2.4% | +3.5% | +16.9% | |
| Q2 2020 | +18.5% | +13.4% | +13.3% | |
| Q1 2020 | +8.1% | +0.6% | +21.4% | |
| Q4 2019 | -2.1% | -9.7% | -29.0% | |
| Q3 2019 | +3.6% | +4.2% | +8.2% | |
| Q2 2019 | +9.9% | +6.1% | +12.0% | |
| Q1 2019 | -1.9% | -2.0% | -11.0% | |
| Q4 2018 | +0.2% | -2.2% | -0.3% | |
| Q3 2018 | -8.7% | -9.9% | -19.4% | |
| Q2 2018 | +4.7% | +1.7% | +3.5% | |
| Q1 2018 | -3.4% | +0.7% | +12.6% | |
| Q4 2017 | +0.5% | -1.8% | +2.2% | |
| Q3 2017 | +9.8% | +19.7% | +24.3% | |
| Q2 2017 | -5.2% | -3.7% | -1.7% | |
| Q1 2017 | +4.9% | +1.0% | +4.7% | |
| Q4 2016 | -3.1% | -2.1% | +2.5% | |
| Q3 2016 | -5.6% | -4.9% | +7.1% | |
| Q2 2016 | -14.3% | -11.7% | -13.1% | |
| Q1 2016 | -9.4% | — | — | |
| Q4 2015 | +4.2% | — | — | |
| Q3 2015 | +12.3% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2014 | -16.8% | — | — | |
| Q1 2014 | +6.1% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +7.1% | — | — | |
| Q2 2013 | +2.3% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2011 | -20.7% | — | — | |
| Q3 2012 | -16.2% | — | — | |
| Q4 2011 | -0.7% | — | — | |
| Q2 2011 | -0.7% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro